Allosteric targeting of receptor tyrosine kinases

The drug discovery landscape has been transformed over the past decade by the discovery of allosteric modulators of all major mammalian receptor superfamilies. Allosteric ligands are a rich potential source of drugs and drug targets with clear therapeutic advantages. G protein–coupled receptors, ligand-gated ion channels and intracellular nuclear hormone receptors have all been targeted by allosteric modulators. More recently, a receptor tyrosine kinase (RTK) has been targeted by an extracellular small-molecule allosteric modulator. Allosteric mechanisms of structurally distinct molecules that target the various receptor families are more alike than originally anticipated and include selectivity, orthosteric probe dependence and pathway-biased signaling.

[1]  E. Jaffe,et al.  Impact of quaternary structure dynamics on allosteric drug discovery. , 2013, Current topics in medicinal chemistry.

[2]  Arthur Christopoulos,et al.  Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.

[3]  T. Blundell,et al.  Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. , 2013, Cancer cell.

[4]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[5]  D. Stein,et al.  Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death , 2007, Proceedings of the National Academy of Sciences.

[6]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[7]  K. McIntyre,et al.  BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.

[8]  Sarel J. Fleishman,et al.  A putative molecular-activation switch in the transmembrane domain of erbB2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Brat,et al.  Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2 , 2013, Science Signaling.

[10]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[11]  T. Kodadek,et al.  A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. , 2008, Journal of the American Chemical Society.

[12]  P P Humphrey,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.

[13]  D. Kirchhofer,et al.  Allosteric Peptide Activators of Pro-Hepatocyte Growth Factor Stimulate Met Signaling , 2010, The Journal of Biological Chemistry.

[14]  A. Christopoulos.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery , 2002, Nature Reviews Drug Discovery.

[15]  Eyal Gottlieb,et al.  Serine is a natural ligand and allosteric activator of pyruvate kinase M2 , 2012, Nature.

[16]  E. Purisima,et al.  Allosteric Noncompetitive Small Molecule Selective Inhibitors of CD45 Tyrosine Phosphatase Suppress T-Cell Receptor Signals and Inflammation In Vivo , 2014, Molecular Pharmacology.

[17]  Bruce J. Melancon,et al.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. , 2012, Journal of medicinal chemistry.

[18]  S. Lazareno,et al.  Allosterism at muscarinic receptors: ligands and mechanisms. , 2005, Mini reviews in medicinal chemistry.

[19]  F. Radvanyi,et al.  Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. , 2013, European journal of medicinal chemistry.

[20]  L. Pike,et al.  The Intracellular Juxtamembrane Domain of the Epidermal Growth Factor (EGF) Receptor Is Responsible for the Allosteric Regulation of EGF Binding*♦ , 2009, Journal of Biological Chemistry.

[21]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[22]  Kenneth Lundstrom,et al.  An Overview on GPCRs and Drug Discovery: Structure-Based Drug Design and Structural Biology on GPCRs , 2009, Methods in molecular biology.

[23]  C. Liebmann,et al.  Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors. , 2012, Cellular signalling.

[24]  J. Katzenellenbogen,et al.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). , 2010, Molecular endocrinology.

[25]  M. Simons,et al.  Non-canonical fibroblast growth factor signalling in angiogenesis. , 2008, Cardiovascular research.

[26]  J. Kuriyan,et al.  Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. , 2011, Molecular cell.

[27]  C. Lebakken,et al.  Detection of Allosteric Kinase Inhibitors by Displacement of Active Site Probes , 2012, Journal of biomolecular screening.

[28]  Brion W. Murray,et al.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors , 2012, Proceedings of the National Academy of Sciences.

[29]  U. Holzgrabe,et al.  Allosteric ligands for G protein‐coupled receptors: A novel strategy with attractive therapeutic opportunities , 2010, Medicinal research reviews.

[30]  J. Schlessinger,et al.  Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling , 2010, Proceedings of the National Academy of Sciences.

[31]  K. Alitalo,et al.  Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. , 2010, Cancer cell.

[32]  C. Pilon,et al.  Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice , 2010, PloS one.

[33]  S. Seshagiri,et al.  The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer , 2013, Nature Reviews Cancer.

[34]  S. Watson,et al.  Improved Glucose Metabolism In Vitro and In Vivo by an Allosteric Monoclonal Antibody That Increases Insulin Receptor Binding Affinity , 2014, PloS one.

[35]  Arthur Christopoulos,et al.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.

[36]  Jie Zhang,et al.  Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. , 2013, Cancer cell.

[37]  John B Wojcik,et al.  Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis , 2011, Cell.

[38]  A. Prota,et al.  Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. , 2010, Biochimica et biophysica acta.

[39]  C. Schäfer,et al.  PKCε acts as negative allosteric modulator of EGF receptor signalling. , 2011, Cellular signalling.

[40]  R. Wallace.  Novel targets for drug discovery , 1996 .

[41]  I. McEwan.  Nuclear hormone receptors: Allosteric switches , 2012, Molecular and Cellular Endocrinology.

[42]  John Kuriyan,et al.  Regulation of the catalytic activity of the EGF receptor. , 2011, Current opinion in structural biology.

[43]  Q. She,et al.  An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo , 2010, Cancer biology & therapy.

[44]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[45]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[46]  J. Wells,et al.  Searching for new allosteric sites in enzymes. , 2004, Current opinion in structural biology.

[47]  G. Superti-Furga,et al.  The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. , 2012, Cancer research.

[48]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[49]  G. Hummer,et al.  Crystal Structure and Allosteric Activation of Protein Kinase C βII , 2011, Cell.

[50]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[51]  Jae-Seong Yang,et al.  Rational Engineering of Enzyme Allosteric Regulation through Sequence Evolution Analysis , 2012, PLoS Comput. Biol..

[52]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[53]  Arthur Christopoulos,et al.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.

[54]  H. Binz,et al.  Targeting Extracellular Domains D4 and D7 of Vascular Endothelial Growth Factor Receptor 2 Reveals Allosteric Receptor Regulatory Sites , 2012, Molecular and Cellular Biology.

[55]  Elodie Laine,et al.  Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase , 2012, PLoS Comput. Biol..

[56]  Joel Morganroth,et al.  Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy , 2013, Drug Safety.

[57]  J. Schlessinger,et al.  Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization , 2008, Proceedings of the National Academy of Sciences.

[58]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[59]  K. Hristova,et al.  Receptor tyrosine kinase transmembrane domains , 2010, Cell adhesion & migration.

[60]  M. V. Vander Heiden,et al.  Allosteric Regulation of PKM2 Allows Cellular Adaptation to Different Physiological States , 2013, Science Signaling.

[61]  D. Leahy.  A molecular view of anti-ErbB monoclonal antibody therapy. , 2008, Cancer cell.

[62]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[63]  K. Alitalo,et al.  Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation , 2013, Proceedings of the National Academy of Sciences.